こころとからだに、
おいしいものを。

Offering delicious products
for the sound mind and body

December 14, 2018

Company: DyDo Group Holdings, Inc.
Representative: Tomiya Takamatsu, President
(Code 2590 on the First Section of the Tokyo Stock Exchange)
Inquiries: Naokazu Hasegawa, Corporate Officer
and General Manager of Corporate Communication Department

DyDo Group Holdings establishes a new company to enter the orphan drug business

Meeting on December 14, 2018, the DyDo Group Holdings Board of Directors resolved to establish a new subsidiary to orchestrate the Company's entry into the orphan drug* business.

1. Purpose of new subsidiary

DyDo Group Holdings announced that it would enter the orphan drug business in March 2018 after identifying the health care market, including the rapidly growing life sciences field, as its next growth domain.

The Company will establish a new subsidiary to facilitate its entry into this new business.

Although the number of pharmaceutical companies developing orphan drugs is growing, small patient populations mean that there are many diseases for which no effective therapeutic agents have yet been developed. This lack of options has become a social issue.

The Group is working to resolve this issue by providing value in the form of pharmaceuticals to patients suffering from rare diseases via this new company. In addition, the Group will continue to pursue the challenge of offering customers delicious, healthy products and services in keeping with its slogan of "Offering delicious products for the sound mind and body" by combining new expertise relating to health and medicine with its existing knowledge base in the areas of drinks, food products, and pharmaceuticals.

2. Overview of new subsidiary

(1) Name	DyDo Pharma, Inc.
(2) Head Office	2-2-7 Nakanoshima, Kita-ku, Osaka
(3) Representative name and position	Yasunori Inaoka, President and Representative Director (Formerly president of POLA PHARMA INC.)
(4) Businesses	Manufacture and sale of pharmaceuticals, medical equipment and devices, and related products
(5) Capital	¥10 million
(6) End of financial year	January
(7) Date of incorporation	January 21, 2019
(8) Start of operations	August 21, 2019 (tentative)
(9) Major shareholders and respective shares	DyDo Group Holdings: 100%

3. Future outlook

The Company plans to announce its financial results for the fiscal year ending January 2019 on March 4, 2019, at which time it will also provide an outlook for its consolidated performance during the fiscal year ending January 2020 that includes forecast results for the new subsidiary.

*As defined by Article 77 Paragraph 2 of Japan's Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices